Skip to main content
. Author manuscript; available in PMC: 2021 Oct 13.
Published in final edited form as: Surgery. 2019 Sep 24;167(1):233–240. doi: 10.1016/j.surg.2019.06.052

Fig 5.

Fig 5.

Treatment of NCI-H295R and SW13 with KU758 decreases aggregate formation in a dose dependent manner with near total inhibition at doses of both 1.0 μM and 2.0 μM KU758 in SW13 and NCI-H295R cells. Aggregate formation after treatment of ACC cells with 1.0 μM 17-AAG is shown for comparison. ACC, adrenocortical carcinoma.